Mesenchymal stem cell-based therapy for type 1 diabetes

Hao Wu, Ram I Mahato

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Diabetes has increasingly become a worldwide health problem, causing huge burden on healthcare system and economy. Type 1 diabetes (T1D), traditionally termed "juvenile diabetes" because of an early onset age, is affecting 5~10% of total diabetic population. Insulin injection, the predominant treatment for T1D, is effective to ameliorate the hyperglycemia but incompetent to relieve the autoimmunity and to regenerate lost islets. Islet transplantation, an experimental treatment for T1D, also suffers from limited supply of human islets and poor immunosuppression. The recent progress in regenerative medicine, especially stem cell therapy, has suggested several novel and potential cures for T1D. Mesenchymal stem cell (MSC) based cell therapy is among one of them. MSCs are a type of adult stem cells residing in bone marrow, adipose tissue, umbilical cord blood, and many other tissues. MSCs, with self-renewal potential and transdifferentiation capability, can be expanded in vitro and directed to various cell lineages with relatively less efforts. MSCs have well-characterized hypoimmunogenicity and immunomodulatory effect. All these features make MSCs attractive for treating T1D. Here, we review the properties of MSCs and some of the recent progress using MSCs as a new therapeutic in the treatment of T1D. We also discuss the strength and limitations of using MSC therapy in human trials.

Original languageEnglish (US)
Pages (from-to)139-143
Number of pages5
JournalDiscovery Medicine
Volume17
Issue number93
StatePublished - 2014

Fingerprint

Cell- and Tissue-Based Therapy
Mesenchymal Stromal Cells
Type 1 Diabetes Mellitus
Islets of Langerhans Transplantation
Adult Stem Cells
Regenerative Medicine
Cell Lineage
Therapeutics
Autoimmunity
Fetal Blood
Age of Onset
Hyperglycemia
Immunosuppression
Adipose Tissue
Stem Cells
Bone Marrow
Insulin
Delivery of Health Care
Injections
Population

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Mesenchymal stem cell-based therapy for type 1 diabetes. / Wu, Hao; Mahato, Ram I.

In: Discovery Medicine, Vol. 17, No. 93, 2014, p. 139-143.

Research output: Contribution to journalArticle

@article{e6789d79262c4e79bff14ba69c42f0d0,
title = "Mesenchymal stem cell-based therapy for type 1 diabetes",
abstract = "Diabetes has increasingly become a worldwide health problem, causing huge burden on healthcare system and economy. Type 1 diabetes (T1D), traditionally termed {"}juvenile diabetes{"} because of an early onset age, is affecting 5~10{\%} of total diabetic population. Insulin injection, the predominant treatment for T1D, is effective to ameliorate the hyperglycemia but incompetent to relieve the autoimmunity and to regenerate lost islets. Islet transplantation, an experimental treatment for T1D, also suffers from limited supply of human islets and poor immunosuppression. The recent progress in regenerative medicine, especially stem cell therapy, has suggested several novel and potential cures for T1D. Mesenchymal stem cell (MSC) based cell therapy is among one of them. MSCs are a type of adult stem cells residing in bone marrow, adipose tissue, umbilical cord blood, and many other tissues. MSCs, with self-renewal potential and transdifferentiation capability, can be expanded in vitro and directed to various cell lineages with relatively less efforts. MSCs have well-characterized hypoimmunogenicity and immunomodulatory effect. All these features make MSCs attractive for treating T1D. Here, we review the properties of MSCs and some of the recent progress using MSCs as a new therapeutic in the treatment of T1D. We also discuss the strength and limitations of using MSC therapy in human trials.",
author = "Hao Wu and Mahato, {Ram I}",
year = "2014",
language = "English (US)",
volume = "17",
pages = "139--143",
journal = "Discovery medicine",
issn = "1539-6509",
publisher = "Discovery Medicine",
number = "93",

}

TY - JOUR

T1 - Mesenchymal stem cell-based therapy for type 1 diabetes

AU - Wu, Hao

AU - Mahato, Ram I

PY - 2014

Y1 - 2014

N2 - Diabetes has increasingly become a worldwide health problem, causing huge burden on healthcare system and economy. Type 1 diabetes (T1D), traditionally termed "juvenile diabetes" because of an early onset age, is affecting 5~10% of total diabetic population. Insulin injection, the predominant treatment for T1D, is effective to ameliorate the hyperglycemia but incompetent to relieve the autoimmunity and to regenerate lost islets. Islet transplantation, an experimental treatment for T1D, also suffers from limited supply of human islets and poor immunosuppression. The recent progress in regenerative medicine, especially stem cell therapy, has suggested several novel and potential cures for T1D. Mesenchymal stem cell (MSC) based cell therapy is among one of them. MSCs are a type of adult stem cells residing in bone marrow, adipose tissue, umbilical cord blood, and many other tissues. MSCs, with self-renewal potential and transdifferentiation capability, can be expanded in vitro and directed to various cell lineages with relatively less efforts. MSCs have well-characterized hypoimmunogenicity and immunomodulatory effect. All these features make MSCs attractive for treating T1D. Here, we review the properties of MSCs and some of the recent progress using MSCs as a new therapeutic in the treatment of T1D. We also discuss the strength and limitations of using MSC therapy in human trials.

AB - Diabetes has increasingly become a worldwide health problem, causing huge burden on healthcare system and economy. Type 1 diabetes (T1D), traditionally termed "juvenile diabetes" because of an early onset age, is affecting 5~10% of total diabetic population. Insulin injection, the predominant treatment for T1D, is effective to ameliorate the hyperglycemia but incompetent to relieve the autoimmunity and to regenerate lost islets. Islet transplantation, an experimental treatment for T1D, also suffers from limited supply of human islets and poor immunosuppression. The recent progress in regenerative medicine, especially stem cell therapy, has suggested several novel and potential cures for T1D. Mesenchymal stem cell (MSC) based cell therapy is among one of them. MSCs are a type of adult stem cells residing in bone marrow, adipose tissue, umbilical cord blood, and many other tissues. MSCs, with self-renewal potential and transdifferentiation capability, can be expanded in vitro and directed to various cell lineages with relatively less efforts. MSCs have well-characterized hypoimmunogenicity and immunomodulatory effect. All these features make MSCs attractive for treating T1D. Here, we review the properties of MSCs and some of the recent progress using MSCs as a new therapeutic in the treatment of T1D. We also discuss the strength and limitations of using MSC therapy in human trials.

UR - http://www.scopus.com/inward/record.url?scp=84896978090&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896978090&partnerID=8YFLogxK

M3 - Article

C2 - 24641956

AN - SCOPUS:84896978090

VL - 17

SP - 139

EP - 143

JO - Discovery medicine

JF - Discovery medicine

SN - 1539-6509

IS - 93

ER -